Dare Bioscience, Inc. (NASDAQ:DARE – Free Report) – Stock analysts at Brookline Capital Markets boosted their Q3 2026 earnings per share estimates for shares of Dare Bioscience in a research note issued to investors on Monday, August 17th. Brookline Capital Markets analyst K. Dolliver now expects that the biotechnology company will post earnings per share of ($0.27) for the quarter, up from their prior forecast of ($0.37). The consensus estimate for Dare Bioscience’s current full-year earnings is ($0.92) per share. Brookline Capital Markets also issued estimates for Dare Bioscience’s Q4 2026 earnings at ($0.24) EPS and FY2026 earnings at ($0.92) EPS.
Several other research firms also recently issued reports on DARE. Benchmark reiterated a “buy” rating on shares of Dare Bioscience in a research note on Monday. Wall Street Zen raised shares of Dare Bioscience to a “hold” rating in a research report on Saturday, May 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Dare Bioscience in a research note on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating on shares of Dare Bioscience in a report on Monday. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Dare Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.
Dare Bioscience Stock Performance
NASDAQ DARE opened at $0.82 on Thursday. Dare Bioscience has a one year low of $0.75 and a one year high of $3.78. The company’s 50 day moving average price is $1.68 and its 200 day moving average price is $1.85. The firm has a market capitalization of $12.61 million, a price-to-earnings ratio of -1.18 and a beta of 1.08.
Dare Bioscience (NASDAQ:DARE – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.10. The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.00 million. Dare Bioscience had a negative return on equity of 748.30% and a negative net margin of 803.80%.
Institutional Trading of Dare Bioscience
Several large investors have recently bought and sold shares of the company. LPL Financial LLC purchased a new stake in shares of Dare Bioscience during the fourth quarter valued at approximately $28,000. Raymond James Financial Inc. boosted its stake in shares of Dare Bioscience by 810.6% in the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 13,650 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Dare Bioscience in the third quarter valued at $37,000. Institutional investors and hedge funds own 6.70% of the company’s stock.
Dare Bioscience Company Profile
Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.
In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.
Featured Articles
- Five stocks we like better than Dare Bioscience
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
